This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue
An interesting, novel approach is to combine Semaglutide with another new molecule – Cagrinitide (Cagri- Sema). This produces greater weight loss than Semaglutide alone says Dr Ambrish Mithal, Chairman, Endocrinology and Diabetes, Max Healthcare